Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
–Multiple vepdegestrant studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib... | May 5, 2023